Eli Lilly and Co

Aktienanalyse zu Eli Lilly and Co (LLY)

$1,208.740

+43.756 (+3.62%)Zum Schluss

Loading chart…
Hoch
1,216.714
Eröffnung
1,177.870
Volumengewichteter Durchschnittskurs
1,199.90
Volumen
3.17M
Marktkap.
863.96B
Tief
1,174.240
Umsatz
3.80B
EV/EBITDA, TTM
19.09

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.

www.lilly.com

KI-Analyse of Eli Lilly and Co (LLY)

Kaufen

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

Analystenbewertungen (22)

Kaufen
13 Kaufen
8 Halten
1 Verkaufen
Aktuell: 1,208.74
Tief
950.00
Durchschnitt
—
Hoch
—

BofA

2026-10-09

Kursziel

—

Kaufen

Cantor Fitzgerald

2026-10-08

Kursziel

—

Übergewichten

Morgan Stanley

2026-10-07

Kursziel

—

Übergewichten

JPMorgan

2026-09-28

Kursziel

—

Übergewichten

Guggenheim

2026-09-18

Kursziel

—

Kaufen

Bewertungskennzahlen

Das aktuelle erwartete KGV von Eli Lilly and Co (LLY) beträgt 24.39, verglichen mit dem 5-Jahres-Durchschnitt von 40.89.

Erwartetes KGV

Unterbewertet
5J-Durchschnitt P/E
40.89
Aktuelles P/E
24.39
Überbewertet
51.90
Unterbewertet
29.88

Erwartetes EV/EBITDA

Unterbewertet
5J-Durchschnitt EV/EBITDA
30.14
Aktuelles EV/EBITDA
19.09
Überbewertet
37.70
Unterbewertet
22.58

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
11.55
Aktuelles P/S
10.29
Überbewertet
13.87
Unterbewertet
9.24

Alphio-AI-Kursszenarien für LLY

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%LLY

$1,138.36

Szenariopreis

B

Basis

Basis · 50%LLY

$934.36

Szenariopreis

B

Bärisch

Bärisch · 25%LLY

$711.76

Szenariopreis

Whales, die LLY halten

C

Corient Private Wealth LP

+ HältLLY

+51.17%

3-Monats-Rendite

P

PKO Towarzystwo Funduszy Inwestycyjnych SA

+ HältLLY

+11.89%

3-Monats-Rendite

C

Compound Global Advisors, LLC

+ HältLLY

+11.66%

3-Monats-Rendite

R

RBC Europe Limited

+ HältLLY

+11.62%

3-Monats-Rendite

B

Banque Pictet & Cie SA

+ HältLLY

+11.36%

3-Monats-Rendite

C

Caixa Econômica Federal

+ HältLLY

+11.31%

3-Monats-Rendite

Event-Zeitleiste

2026-10-14 (ET)

10:00:00

UnitedHealth and Others See Notable Gains

2026-10-13 (ET)

07:30:00

Prelude Therapeutics Announces Clinical Trial Collaboration with Eli Lilly

2026-10-09 (ET)

07:00:00

Eli Lilly Announces New Data from TOGETHER-PsO Trial

2026-10-05 (ET)

08:30:00

Gate Bioscience Expands Collaboration with Eli Lilly, Potential Value Exceeds $870M

News

LLY FAQ – beantwortet von Alphio AI

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.

Community

Mehr ↗
RektUrchinvor 19 Std.

Rotation into defensive sectors like healthcare this morning. Here's $LLY, which continues to set up constructively.

Mehr anzeigen
0xLunarbazaar21.9.2026

$SPY $DKNG $LLY $PSKY $VLVLY 1) In a post on Truth Social, President Trump states: "...I will be announcing, in the near future, the AI 'Czar' - Only High I.Q. individuals need apply! AI is the next Industrial Revolution, or Internet, but will be even larger and more impactful, possibly as much as 25% of our Country's GDP. We are leading China, and the rest of the World, and I intend to keep it that way!" 2) DraftKings (DKNG) puts customer betting records into a machine learning model to find out who is most likely to make losing bets, Alex Klavens, Walt Bogdanich and Jenny Vrentas of New York Times report. The company uses data science to target losing gamblers with promotions that encourage more betting, six former employees told the Times. 3) Some emerging scientific research points to an increased risk for GLP-1 patients to develop nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. 4) Paramount (PSKY) and states looking to block its acquisition of Warner Bros. (WBD) could settle as soon as this week, Jody Godoy of Reuters reports, citing sources familiar with the matter. A commitment on the number of movie releases is among the terms of the settlement, the sources added. 5) The Board of Directors of Volvo Cars (VLVLY) has appointed Klaus Zellmer as President and Chief Executive Officer. Klaus Zellmer will assume the position no later than 1 October 2027. Hakan Samuelsson will, together with the Board, ensure a seamless transition. Klaus Zellmer most recently served Chairman of the Board of Management and CEO of Skoda Auto, a Volkswagen (VWAGY) company.

Mehr anzeigen
0xLunarbazaar19.9.2026

$LLY $NVO Lilly and Novo face lawsuits over GLP-1 vision loss risk, WSJ says. Some emerging scientific research points to an increased risk for GLP-1 patients of developing nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of the Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. Evidence of the vision loss risk is mixed and not clear enough to say whether or how the drugs cause the condition, doctors and researchers said, according to the Journal.

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten